Cytotoxic chemotherapy in advanced non-small cell lung cancer: A review of standard treatment paradigms

Clinical Cancer Research

Volumn 10, Issue 12 II, 2004, Pages

  Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR;

ANEMIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; TUMOR MARKERS, BIOLOGICAL;

EID: 3042673101     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-040009     Document Type: Conference Paper

References (48)

1. The Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311: 899-909.
2. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-94.
3. Stephens R, Fairlamb N, Gower N, et al. The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 2002;21:291a.
4. Ranson M, Davidson N, Nicolson M. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2000;92:1074-80.
5. Roszkowski K, Pluzanska A, Krzakowski M. A multicenter, randomized phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or nonresectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145-57.
6. The Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival in elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
7. Breathnach O, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol 2001;19:1734-42.
8. Thongprasert S, Sanuganmitra P, Juthapan N. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSc) versus BSC plus chemotherapy. Lung Cancer 1999;24:17-24.
9. Bunn PJ, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;5:1087-100.
10. Baggstrom M, Socinski MA, Hensing T, Poole C. Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol 2002;21:306a.
11. Yana T, Takada M, Origasa H, Ijima T, Yamamoto N, Nakagawa K, Fukuoka M. New chemotherapy agent plus platinum for advanced non-small cell lung cancer: a meta-analysis. Pro Am Soc Clin Oncol 2002;21:328a.
12. Kelly K, Crowley J, Bunn P, Presant C, Grevstad P, Moinpour C. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
13. Schiller J, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
14. Van Meerbeeck J, Sarit E, Lianes P, et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:308a.
15. Scagliotti G, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002;20:4285-91.
16. Aberola V, Camps C, Provencia M, Isla D, Rosell R, Vadell C. Cisplatin plus gemcitabine (CG) vs a cisplatin-based triplet vs nonplatinum sequential doublets in advanced non-small cell lung cancer (NSCLC): a Spanish Lung Cancer Group phase III randomized trial (GEPC/98-02). J Clin Oncol 2003;21:3207-13.
17. Lilenbaum R, Herndon J, List M, et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, qualify of life (QoL), and cost-effectiveness. Proc Am Soc Clin Oncol 2002;21:1a.
18. Fossella F, Pereira J, van Pawel J, et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J Clin Oncol 2003;21:3016-24.
19. Sederholm C. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study of by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 2002;21:291a.
20. Delbaldo C. Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small cell lung carcinoma (NSCLC): a meta-analysis of the lietrature. Proc Am Soc Clin Oncol 2003;22:623.
21. Baggstrom M, Socinski MA, Hensing T, Poole C. Addressing the optimal number of cytotoxic agents in stage IIIB/IV non-small cell lung cancer (NSLCC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol 2003;21:306a.
22. Bunn P. Chemotherapy for advanced non-small cell lung cancer: who, what, when, why. J Clin Oncol 2002;20:23s-33s.
23. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578-85.
24. Georgoulias V, Papadakis E, Alexopoulos A. Platinum-based and non-platinum based chemotherapy in advanced non-small lung cancer: a randomized multicenter trial. Lancet 2001;357:1478-84.
25. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3025-34.
26. Scagliotti G, Kortsik C, Castellano D, et al. Phase II randomized study of pemetrexed + carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer. Pro Am Soc Clin Oncol 2003;22:625.
27. Rosell R, Gatzemeier U, Betticher D, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advancd non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13:1539-49.
28. Smith I, O'Brien M, Talbot D. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-43.
29. Socinski MA, Schell M, Peterman A, Bakri K, Yates S, Gitten R. A phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage IIIB/IV non-small cell lung cancer. J Clin Oncol 2002;20:1335-43.
30. Andresen O, Sorenson S, Bergman B, Sundstrom S, Vilsvik J. Duration of chemotherapy and survival in advanced non-small cell lung cancer (NSCLC). A multicenter, prospective randomised study. Lung Cancer 2003;41:S28.
31. DePierre A, Quoix E, Mercier M, Breton J, Moro-Sibilot D, Debieuvre D. Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): a randomized study of vinorelbine (V) versus observation (OB) in patients (Pts) responding to induction therapy (French Cooperative Oncology Group). Proc Am Soc Clin Oncol 2001;20:309a.
32. Langer C, Manola J, Bernardo P, Kugler J, Bonomi A, Cella D. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-81.
33. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel Cancer 2003;98:779-88.
34. Kelly K, Giarritta S, Hayes S, Akerley W, Hesketh P, Wozniak A. Should older patients (Pts) receive combination chemotherapy for advanced non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials.9509 and 9308. Proc Am Soc Clin Oncol 2001;20:329a.
35. Yancik R, Ries LA. Cancer in the older persons: magnitude of the problem. In: L. Balducci, G. Lyman, and W. Ershler (eds.), Comprehensive Geriatric Oncology. The Netherlands: Harwood Academic Publishers, Amsterdam, 1998. p. 95-104.
36. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000;36:453-71.
37. Gridelli G, Perrone F, Cigolari S, Manzione L, Piantadosi F, Barbera S. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients. Proc Am Soc Clin Oncol 2001;20:308a.
38. Sweeney C, Zhu J, Sandler A, Schiller J, Belani C, Langer C. Outcome of Patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594. A phase III trial in patients with metastatic non-small cell lung carcinoma. Cancer 2001;92:2635-47.
39. Crino L, Norello S, Migliorino M. A phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer (NSCLC): Impact of PS=2 vs 0 or 1 and age ≥ 70 vs ≤ 70 on chemotherapy outcome. Proc Am Soc Clin Oncol 2002;21:315a.
40. Shepherd F, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
41. Fossella F, Devore R, Kerr R, Crawford J, Natale R, Dunphy F. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-60.
42. Gridelli C, Illiano A, Salvagni S, et al. Effect on quality-of-life (Qol) of weekly vs 3-weekly docetaxel (D) in second-line treatment of advanced non-small cell lung cancer. The DISTAL randomized phase 3 study. Pro Am Soc Clin Oncol 2003;22:625.
43. Camps C, Massuti B, Jimenez A, et al. Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small cell lung cancer (NSCLC): A Spanish Lung Cancer Group (SLCG) phase III trial. Pro Am Soc Clin Oncol 2003;22:625.
44. Socinski MA, Schell M, Bakri K, et al. Second-line low-dose weekly paclitaxel in patients with stage IIIB/IV non-small cell lung cancer failing first-line carboplatin/paclitaxel. Cancer 2002;95:1265-73.
45. Hanna N, Shepherd F, Rosell R, et al. A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc Am Soc Clin Oncol 2003;22:622.
46. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
47. Perez-Soler R, Chachona A, Huberman M, Karp D, Rigas J, Hammond L. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:310a.
48. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 2003;290:2149-58.